JP MORGAN/CALL/ELI LILLY & CO/810/0.01/17.01.25 | Market Closed - Börse Stuttgart 09:46:04 31/05/2024 BST | ||
| 0.94 EUR | +5.62% |
|
| 1 month | +62.07% | ||
| 3 months | +16.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.94 | +5.62% |
| 30/05/24 | 0.89 | +2.30% |
| 29/05/24 | 0.87 | -3.33% |
| 28/05/24 | 0.9 | +1.12% |
| 27/05/24 | 0.89 | -1.11% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 09:46 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK27V4 |
| ISIN | DE000JK27V43 |
| Date issued | 08/02/2024 |
| Strike | 810 $ |
| Maturity | 17/01/2025 (229 Days) |
| Parity | 100 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.01 € |
|---|---|
| Lowest since issue | 0.55 € |
| Spread | 0.01 € |
| Spread % | 1.05% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- Warrant
